ArticleIndian dermatology online journal2025
Long-Term Therapeutic Outcomes with Cladribine in Patients with Xanthoma Disseminatum.
Article in Indian dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractCladribine (2-chlorodeoxyadenosine or 2CdA) is a purine analogue that has been used in various non-Langerhans cell histiocytosis. We present a case series of six patients with xanthoma disseminatum having systemic involvement, treated with monthly cladribine for three to 12 cycles (median six cycles), leading to 63.3% improvement at the end of treatment, increasing to 75% at the end of 2.1 ± 1.6 years of follow-up. Three patients maintained their response, two continued to improve without further intervention, and one patient relapsed with partial response to reinstitution of therapy. Intracranial lesions improved significantly in all three patients with neurological involvement. One patient with severe laryngeal involvement causing stenosis was able to avoid tracheostomy. Cladribine was largely well tolerated. Half of the patients developed transient leucopenia requiring prophylactic granulocyte colony-stimulating factor, but none of the patients developed any serious infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.